David Becker, MD, FACC, Director of the Preventive and Integrative Heart Health Program at the Temple Heart and Vascular Institute, wrote a blog post for the Philadelphia Inquirer about “the top 10 heart health developments in 2021.”
David Becker, MD, FACC, Director of the Preventive and Integrative Heart Health Program at the Temple Heart and Vascular Institute, wrote a blog post for the Philadelphia Inquirer about “the top 10 heart health developments in 2021.”
Patients who received tezepelumab vs. placebo had less healthcare resource utilization; and fewer patients on tezepelumab vs. placebo received systemic corticosteroids for COPD exacerbations.
Read MoreThe analysis looked at sotatercept use in patients with pulmonary arterial hypertension and the safety and utilization across phenotype groups.
Read More